Stephanie Seasly, MD
Addiction Medicine · New York, NYNPI 1336405711
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Collegium Pharmaceutical, Inc. at 29.8% of the total. Reporting peaked in 2019 at $561 and has fallen 73.9% since, to $146 in 2021.
Across 56 payments — averaging $14.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$247
- Sentynl Therapeutics, Inc.$124
- Daiichi Sankyo Inc.$119
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$118
- Orexo US, Inc.$83
- Biodelivery Sciences International, Inc.$79
- plus $59 from 3 others
What the payments were for
- Food & beverage$829100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 15 | $247 |
| Sentynl Therapeutics, Inc. | 15 | $124 |
| Daiichi Sankyo Inc. | 11 | $119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $118 |
| Orexo US, Inc. | 4 | $83 |
| Biodelivery Sciences International, Inc. | 5 | $79 |
| Redhill Biopharma Inc. | 2 | $30 |
| Kaleo, Inc. | 1 | $16 |
| Amgen | 1 | $13 |
How this compares
$829 in reported general payments places this provider in the 70th percentile of 125 addiction medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 16 | $20,965 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in New York
- John MarianiNew York$38K
- Stefan KantrowitzNew York$33K
- Ramon RaveloNew York$13K
- Stuart GitlowNew York$7K
- James WolbergNew York$5K
- Joshua LeeNew York$1K
- Lloyd ZimmermanNew York$1K
- James McKnightNew York$694
- Elias DakwarNew York$514
- Alina BabarNew York$334
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.